Committed to serving the COPD community, AstraZeneca’s BREZTRI team is unveiling their latest, direct-to-consumer US advertising campaign, “Get Real.”

Bayer, Brigham and Women’s Hospital, and Massachusetts General Hospital launched a joint laboratory to research new drugs to treat chronic lung diseases.

Dynavax Technologies shares fell more than 5 percent after the company reported that an asthma drug being jointly developed with AstraZeneca failed to meet endpoints in a mid-stage trial.

People with chronic obstructive pulmonary disease (COPD) who use long-acting inhaled bronchodilators may have an increased risk of heart attacks and strokes right after they start taking these medicines, a Taiwanese study suggests.

Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration approved the New Drug Application for Lonhala Magnair (glycopyrrolate) Inhalation Solution (25 mcg twice daily) – also known as SUN-101/eFlow – for the long-term, maintenance treatment of airflow obstruction in people with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

GlaxoSmithKline said a European Medicines Agency (EMA) panel recommended for approval the company’s three-in-one inhaled lung drug.

Chiesi Group announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending marketing authorization for the extrafine triple combination ICS/LABA/LAMA, under the brand name Trimbow, for the first time in a single inhaler for the treatment of Chronic Obstructive Pulmonary Disease.

AstraZeneca entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the non-U.S. rights to Rhinocort Aqua.

Fresh off its filing for a new COPD drug, Massachusetts-based Sunovion Pharmaceuticals struck a $642 million deal to acquire Toronto-based Cynapsus Therapeutics and its Parkinson’s disease drug candidate.

Drugmaker Vectura Group Plc said its asthma therapy Flutiform had not met the primary endpoint in a late-stage trial to determine its ability to treat COPD.